Prediction of relapse activity when switching to cladribine for multiple sclerosis.
Michael ZhongAnneke Van Der WaltMastura MonifSuzanne HodgkinsonSara EichauTomas KalincikJeannette Lechner-ScottKatherine BuzzardOlga SkibinaVincent Van PeschErnest ButlerJulie PrevostMarc GirardJiwon OhHelmut ButzkuevenVilija G JokubaitisPublished in: Multiple sclerosis (Houndmills, Basingstoke, England) (2022)
Relapse during or prior to the treatment gap, and younger age, are of prognostic relevance in the year after switching to cladribine. Switching from NTZ is also independently associated with greater relapse hazard.